作者:Jeremy L. Yap、Huabo Wang、Angela Hu、Jay Chauhan、Kwan-Young Jung、Robert B. Gharavi、Edward V. Prochownik、Steven Fletcher
DOI:10.1016/j.bmcl.2012.10.013
日期:2013.1
relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1′-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) – which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues – was executed in order to determine its pharmacophore. Whilst the 7-nitrobenzofurazan was found to be critical for inhibitory activity, the ortho-biphenyl could be replaced with
c-Myc (Myc) 抑制剂 10074-G5 ( N -([1,1'-biphenyl]-2-yl)-7-nitrobenzo[ c ][1,2, 5]oxadiazol-4-amine, 1 ) – 其目标是侧翼为精氨酸残基的 Myc 癌蛋白的疏水结构域 – 被执行以确定其药效团。虽然发现 7-硝基苯并呋喃对抑制活性至关重要,但邻联苯可以被对羧基苯基取代以提供新的抑制剂 JY-3-094 ( 3q )。大约是 IC 50铅的效力的五倍33 μM 用于破坏 Myc-Max 异源二聚体,JY-3-094 表现出优于 Max-Max 同源二聚体的选择性,在 100 μM 时没有明显影响。重要的是,JY-3-094 的羧酸改善了先导化合物的理化性质,这将有助于引入额外的疏水性,从而进一步增强 Myc 抑制活性。